- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Dewpoint Therapeutics secures funding for DPTX3186 development | ||
| Do | Odyssey Therapeutics raises $213m via Series D | ||
| Mi | FDA grants breakthrough therapy status to Ionis ION582 to treat Angelman syndrome | ||
| Di | Novonesis and Novo Nordisk collaborate on gut microbiome research initiative | ||
| Mo | Takeda receives FDA approval for Vonvendi sBLA | ||
| 05.09. | FDA grants breakthrough therapy status to Eli Lilly's olomorasib | ||
| 04.09. | Andelyn and Tern partner for gene therapy to treat CLN2 Batten disease | ||
| 03.09. | Polpharma Biologics signs biosimilars licensing deals with MS Pharma | ||
| 02.09. | OMass signs deal with Genentech for IBD small molecules | ||
| 01.09. | FDA approves Eisai and Biogen's Leqembi Iqlik BLA for early Alzheimer's | ||
| 29.08. | EMA grants orphan designation to Aldeyra's ADX-2191 for vitreoretinal lymphoma | ||
| 28.08. | Leal Therapeutics raises $30m in Series A funding for neuro-metabolic therapies | ||
| 26.08. | FDA expands Amgen's Repatha use to adults at risk of cardiovascular events | ||
| 25.08. | Piramal Pharma opens oral solid dosage suite in Pennsylvania, US | ||
| 22.08. | BeOne Medicines receives EC approval for Brukinsa tablet formulation | ||
| 21.08. | BMS Secures Health Canada approval for dual immunotherapy | ||
| 20.08. | Santhera signs deal with Uniphar for GCC distribution of Agamree | ||
| 19.08. | FDA grants orphan drug status to Soligenix's dusquetide | ||
| 18.08. | Halda receives FDA fast track status for HLD-0915 to treat prostate cancer | ||
| 14.08. | BioDlink's bevacizumab receives marketing approval in Colombia, Pakistan | ||
| 13.08. | Southern Research opens new biotech centre in Alabama | ||
| 12.08. | FDA gives approval to Viatris for Iron Sucrose Injection | ||
| 11.08. | Annexon announces EMA selection of vonaprument for PDC pilot participation | ||
| 08.08. | Intas Pharmaceuticals acquires Udenyca from Coherus BioSciences | ||
| 07.08. | Cingulate submits NDA for CTx-1301 for ADHD treatment |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .